Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
67.49
+0.95 (+1.43%)
4:00:02 PM EDT: $67.54 +0.05 (+0.07%)
Products, Regulatory, Other Pre-Announcement

Immunomedics Announces Positive Results From Pivotal Phase 2 TROPHY U-01 Study Of Trodelvy In Metastatic Urothelial Cancer

Published: 09/19/2020 15:07 GMT
Gilead Sciences, Inc. (GILD) - Immunomedics Announces Positive Results From Pivotal Phase 2 Trophy U-01 Study of Trodelvy in Metastatic Urothelial Cancer (muc).
Immunomedics - Trodelvy Achieves a 27% Orr & 5.9-month Median Duration of Response in Heavily-pretreated Patients With Muc.
Immunomedics - Sbla Submission for Accelerated Approval Expected in Q4, Pending FDA Final Guidance for Trodelvy in Metastatic Urothelial Cancer.
Immunomedics - Phase 3 Tropics-04 Study in Third-line Muc Underway.
Immunomedics - 1 Treatment-related Death in Trophy U-01 Study From Sepsis Due to Febrile Neutropenia.
Immunomedics - Trodelvy Demonstrated Tolerable & Predictable Safety Profile Consistent With Previous Observations.